References
Uncategorized References
1. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis:
Strategies that increase life expectancy and improve quality of life.American Journal of Respiratory and Critical Care Medicine.2011;183(11):1463-1471.
2. Sturgess JM. Structural and developmental abnormalities of the
exocrine pancreas in cystic fibrosis. J Pediatr Gastroenterol
Nutr. 1984;3 Suppl 1:S55-66.
3. Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic
fibrosis, and its treatment. Clinical Nutrition.2000;19(6):387-394.
4. Scott RB, O’Loughlin EV, Gall DG. Gastroesophageal reflux in patients
with cystic fibrosis. The Journal of Pediatrics.1985;106(2):223-227.
5. Vaisman N, Pencharz PB, Corey M, Canny GJ, Hahn E. Energy expenditure
of patients with cystic fibrosis. J Pediatr. 1987;111(4):496-500.
6. Calella P, Valerio G, Brodlie M, Donini LM, Siervo M. Cystic
fibrosis, body composition, and health outcomes: a systematic review.Nutrition. 2018;55-56:131-139.
7. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of
survival, growth, and pulmonary function in patients with cystic
fibrosis in Boston and Toronto. Journal of Clinical Epidemiology.1988;41(6):583-591.
8. Kastner-Cole D, Palmer CNA, Ogston SA, Mehta A, Mukhopadhyay S.
Overweight and Obesity in ΔF508 Homozygous Cystic Fibrosis. The
Journal of Pediatrics. 2005;147(3):402-404.
9. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body
composition in adult patients with cystic fibrosis. Thorax.1993;48(6):589.
10. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H.
Evidence-Based Practice Recommendations for Nutrition-Related Management
of Children and Adults with Cystic Fibrosis and Pancreatic
Insufficiency: Results of a Systematic Review. Journal of the
American Dietetic Association. 2008;108(5):832-839.
11. Sullivan JS, Mascarenhas MR. Nutrition: Prevention and management of
nutritional failure in Cystic Fibrosis. J Cyst Fibros. 2017;16
Suppl 2:S87-s93.
12. Egan ME. Cystic fibrosis transmembrane conductance receptor
modulator therapy in cystic fibrosis, an update. Curr Opin
Pediatr. 2020;32(3):384-388.
13. Bailey J, Rozga M, McDonald CM, et al. Effect of CFTR Modulators on
Anthropometric Parameters in Individuals with Cystic Fibrosis: An
Evidence Analysis Center Systematic Review. J Acad Nutr Diet.2020.
14. Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic
fibrosis: A center-based analysis. Pediatric Pulmonology.2015;50(1):35-41.
15. Gelfond D, Heltshe S, Ma C, et al. Impact of CFTR Modulation on
Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic
Fibrosis and the G551D Mutation. Clinical and Translational
Gastroenterology. 2017;8(3).
16. Edgeworth D, Keating D, Ellis M, et al. Improvement in exercise
duration, lung function and well-being in G551D-cystic fibrosis
patients: A double-blind, placebo-controlled, randomized, cross-over
study with ivacaftor treatment. Clinical Science.2017;131(15):2037-2045.
17. Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy
Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic
Fibrosis Gating Mutations. Journal of Pediatrics.2018;201:229-237.e224.
18. https://www.cdc.gov/healthyweight/bmi/calculator.html.
19. http://gli-calculator.ersnet.org/
20. Cystic Fibrosis Foundation Patient Registry 2020 Annual Data
Report. Cystic Fibrosis Foundation;2021.
Table 1. General characteristics of study participants